文献速递肝病

因NASH肝硬化接受肝移植患者的生存影响因素:NailNASH联盟数据

Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-02-18

该研究分析1997至2017年7个移植中心938例因NASH肝硬化行肝移植患者,中位随访3.8年,1、3、5、10、15年生存率分别为93%、88%、83%、69%、46%。多变量分析显示年龄>65岁、终末期肾病、黑人种族及非钙调神经磷酸酶抑制剂方案与死亡率升高相关,移植后使用他汀与生存改善相关。

要点

  • 因NASH肝硬化行肝移植者长期生存良好,1、3、5、10、15年生存率分别为93%、88%、83%、69%、46%。
  • 年龄>65岁、终末期肾病、黑人种族及非钙调神经磷酸酶抑制剂方案与死亡风险升高独立相关。
  • 移植后使用他汀与生存改善相关(HR 0.38),在所有亚组中均与生存改善相关。

核心结论

  • 尽管长期生存良好,因NASH肝硬化接受肝移植且年龄>65岁或移植时合并2型糖尿病的患者死亡率更高;移植后使用他汀可减弱风险并与生存改善相关。

研究设计与样本

  • 多中心回顾性队列研究,纳入1997至2017年7个移植中心(NailNASH联盟)因NASH肝硬化接受肝移植的患者938例,中位随访3.8年(四分位距1.60-7.05年)。

主要发现

  • 队列1、3、5、10、15年生存率分别为93%、88%、83%、69%、46%。
  • 195例死亡中最常见死因为感染(19%)、心血管疾病(18%)、癌症(17%)和肝脏相关(11%)。
  • 年龄>65岁与死亡率升高相关(HR 1.70;95%CI 1.04-2.77;P=.04)。
  • 终末期肾病(HR 1.55;95%CI 1.04-2.31;P=.03)、黑人种族(HR 5.25;95%CI 2.12-12.96;P=.0003)及非钙调神经磷酸酶抑制剂方案(HR 2.05;95%CI 1.19-3.51;P=.009)与死亡率升高相关。
  • 移植后使用他汀与生存改善相关(HR 0.38;95%CI 0.19-0.75;P=.005)。

临床怎么用

  • 作者认为,仔细选择患者及对代谢合并症实施基于方案的管理可能进一步改善临床结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is the leading indication for liver transplant (LT) in women and the elderly. Granular details into factors impacting survival in this population are needed to optimize management and improve outcomes. METHODS: Patients receiving LT for NASH cirrhosis from 1997 to 2017 across 7 transplant centers (NailNASH consortium) were analyzed. The primary outcome was all-cause mortality, and causes of death were enumerated. All outcomes were cross referenced with United Network for Organ Sharing and adjudicated at each individual center. Cox regression models were constructed to elucidate clinical factors impacting mortality. RESULTS: Nine hundred thirty-eight patients with a median follow-up of 3.8 years (interquartile range, 1.60-7.05 years) were included. The 1-, 3-, 5-, 10-, and 15-year survival of the cohort was 93%, 88%, 83%, 69%, and 46%, respectively. Of 195 deaths in the cohort, the most common causes were infection (19%), cardiovascular disease (18%), cancer (17%), and liver-related (11%). Inferior survival was noted in patients >65 years. On multivariable analysis, age >65 (hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.04-2.77; P = .04), end-stage renal disease (HR, 1.55; 95% CI, 1.04-2.31; P = .03), black race (HR, 5.25; 95% CI, 2.12-12.96; P = .0003), and non-calcineurin inhibitors-based regimens (HR, 2.05; 95% CI, 1.19-3.51; P = .009) were associated with increased mortality. Statin use after LT favorably impacted survival (HR, 0.38; 95% CI, 0.19-0.75; P = .005). CONCLUSIONS: Despite excellent long-term survival, patients transplanted for NASH at >65 years or with type 2 diabetes mellitus at transplant had higher mortality. Statin use after transplant attenuated risk and was associated with improved survival across all subgroups, suggesting that careful patient selection and implementation of protocol-based management of metabolic comorbidities may further improve clinical outcomes.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rinella ME, Satapathy SK, Brandman D, et al. Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. Clin Gastroenterol Hepatol. 2022. PMID: 35189388. doi:10.1016/j.cgh.2022.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。